Chordoma: A case series and review of the literature

被引：24

作者：

Alan O. ^{[1
,2
]}

Akin Telli T. ^{[1
,2
]}

Ercelep O. ^{[1
,2
]}

Tanrikulu Simsek E. ^{[1
,2
]}

Basoglu Tuylu T. ^{[1
,2
]}

Mutis A. ^{[2
]}

Hasanov R. ^{[1
,2
]}

Kaya S. ^{[1
,2
]}

Akgül Babacan N. ^{[1
,2
]}

Dane F. ^{[1
,2
]}

Yumuk P.F. ^{[1
,2
]}

机构：

[1] Division of Medical Oncology, Department of Internal Medicine, Marmara University, Faculty of Medicine, Istanbul

[2] Department of Internal Medicine, Marmara University, Faculty of Medicine, Istanbul

来源：

Journal of Medical Case Reports | / 12卷 / 1期

关键词：

Advanced chordoma; Rare disease; Targeted therapy; Tyrosine kinases;

D O I：

10.1186/s13256-018-1784-y

中图分类号：

学科分类号：

摘要：

Background: Chordoma is a rare malignant tumor of the skull base and axial skeleton, with an incidence of less than 0.1/100,000 per year. Patients with advanced chordoma have a poor prognosis due to locoregional recurrence with infiltration and destruction of surrounding bone and soft tissue. Cytotoxic chemotherapy or other systemic therapies have not been proven to be effective for these diseases. Therefore, several molecularly targeted therapies have been proposed as potentially beneficial, including tyrosine kinase inhibitors such as imatinib, sorafenib, lapatinib, and others. Case presentation: We present three cases of advanced chordoma treated with molecular targeted therapies: a 52-year-old Caucasian man, a 72-year-old Caucasian woman, and a 38-year-old Caucasian woman. Conclusions: Chordoma has few systemic treatment options and they have limited benefit. Randomized trials with large patient numbers are unfeasible in this rare disease. Targeted therapy might be a reasonable alternative treatment for chordoma. Still, new treatment strategies are needed for this rare disease. © 2018 The Author(s).

引用

共 16 条

[1]

Stiller C.A., Trama A., Serraino D., Rossi S., Navarro C., Chirlaque M.D., Casali P.G., Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project, Eur J Cancer, 49, 3, pp. 684-695, (2013)

[2]

Fletcher C.D.M., Bridge J.A., Hogendoorn P., Mertens F., Editors, WHO Classification of Tumours of Soft Tissue and Bone, pp. 328-329, (2013)

[3]

Stacchiotti S., Sommer J., Building a global consensus approach to chordoma: A position paper from the medical and patient community, Lancet Oncol, 16, pp. e71-e83, (2015)

[4]

Moojen W.A., Vleggeert-Lankamp C.L., Krol A.D., Dijkstra S.P., Long-term results: Adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable, Spine, 36, pp. E656-E661, (2011)

[5]

Delaney T.F., Liebsch N.J., Pedlow F.X., Adams J., Dean S., Yeap B.Y., McManus P., Rosenberg A.E., Nielsen G.P., Harmon D.C., Spiro I.J., Raskin K.A., Suit H.D., Yoon S.S., Hornicek F.J., Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas, Int J Radiat Oncol Biol Phys, 74, pp. 732-739, (2009)

[6]

Nishida Y., Kamada T., Imai R., Tsukushi S., Yamada Y., Sugiura H., Shido Y., Wasa J., Ishiguro N., Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery, Int J Radiat Oncol Biol Phys, 79, pp. 110-116, (2011)

[7]

Radelli S., Stacchiotti S., Et al., Sacral Chordoma: Long-term outcome of a large series of patients surgically treated at two reference centers, Spine (Phila Pa 1976), 41, 12, pp. 1049-1057, (2016)

[8]

Tamborini E., Miselli F., Negri T., Et al., Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA and KIT receptors in chordomas, Clin Cancer Res, 12, pp. 6920-6928, (2006)

[9]

Weinberger P.M., Yu Z., Kowalski D., Et al., Differential expression of EGFR, c-Met, and HER2/neu in chordoma compared with 17 other malignancies, Arch Otolaryngol Head Neck Surg, 131, pp. 707-711, (2005)

[10]

Stacchiotti S., Longhi A., Ferraresi V., Et al., Phase II study of imatinib in advanced chordoma, J Clin Oncol, 30, pp. 914-920, (2012)

← 1 2 →